Divalent metal transporter 1 (DMT1), whose mRNA possesses a stem-loop structure in 3′-untranslated region, has been identified in most organs and responsible for transport of various divalent metal ions. Previous work from this laboratory has shown that manganese (Mn) exposure alters the function of iron regulatory protein (IRP) and increases iron (Fe) concentrations in the cerebrospinal fluid (CSF). This study was designed to test the hypothesis that Mn treatment, by acting on protein-mRNA binding between IRP and DMT1 mRNA, altered the expression of DMT1 in an immortalized choroidal epithelial Z310 cell line which was derived from rat choroid plexus epithelia, leading to a compartmental shift of Fe from the blood to the CSF. Immunocytochemistry confirmed the presence of DMT1 in Z310 cell. Following in vitro exposure to Mn at 100 μM for 24 and 48 h, the expression of DMT1 mRNA in Z310 cells was significantly increased by 45.4% (P < 0.05) and 78.1% (P < 0.01), respectively, as compared to controls. Accordingly, Western blot analysis revealed a significant increase of DMT1 protein concentrations at 48 h after Mn exposure (100 μM). 
Introduction
Divalent metal transporter 1 (DMT1), also known as divalent cation transporter 1 (DCT1) or Nramp2 (natural resistanceassociated macrophage protein 2), was first identified in mice as a gene homologous to the previously described Nramp (Gruenheid et al., 1995) and subsequently characterized by Gunshin and co-workers as mammalian proton-coupled metal-ion transporter (Gunshin et al., 1997) . DMT1, as an integral membrane protein, plays an important role in iron (Fe) transport across the cell membrane . In addition, DMT1 nonselectively transports multiple divalent metals including manganese (Mn), copper (Cu), cobalt (Co), zinc (Zn), cadmium (Cd) and lead (Pb) (Gunshin et al., 1997) . DMT1 is most abundantly expressed in the duodenal epithelia.
The expression of DMT1 in other cell types of nearly most of the organs has also been identified including erythrocytes, renal epithelial cells, cardiomyocytes and human placenta epithelia (Ferguson et al., 2001; Georgieff et al., 2000; Ke et al., 2003; Levy et al., 1999) . In brain, DMT1 exists in neurons, cerebral capillary endothelial cells that constitute the bloodbrain barrier (BBB) and the choroid plexus epithelial cells that comprise the blood-CSF barrier (BCB) (Burdo et al., 2001; Siddappa et al., 2003; Siddappa et al., 2002) . The presence of DMT1 in brain barriers is functionally important with regard to the necessity of stable homeostasis of essential elements in brain extracellular fluids for normal brain function. However, the question as to how DMT1 regulates the homeostasis of iron and other metals in the central nervous system (CNS) remains unanswered. As a trans-membrane protein, the structure of DMT1 possesses two alternate splicing isoforms that result from the mRNA transcripts with distinct alternative 3′-untranslated regions (UTR) (Konarska and Sharp, 1986 ). There are two major DMT1 mRNA transcripts, one of which contains an iron responsive element (IRE) with a stem-loop structure available for interaction with cellular proteins (Addess et al., 1997; Eisenstein and Ross, 2003; Rouault, 2001 ). The similar stemloop structure of IRE has also been identified and characterized in mRNAs encoding transferrin receptor (TfR) (Fig. 1) ; the latter is important for delivering transferrin-bound iron to CNS via brain capillaries and choroid plexus (Deane et al., 2004) . Noticeably, the IRE structure in TfR mRNA binds specifically to a protein known as iron regulatory protein-1 (IRP1), whose active center contains a [4Fe-4S] cluster. In the Fe-deficient condition, IRP1 binds with a high affinity to IRE containing TfR mRNAs, stabilizes TfR expression and increases intracellular levels of TfR (Andrews, 1999; Klausner et al., 1993; Li et al., 2005) . It is unclear, however, whether the cellular levels of DMT1 are regulated in the same fashion as the TfR.
Human exposure to manganese results in symptoms highly similar to Parkinson's disease. Increased use of manganese as a gasoline additive and the ensuing public health hazard have demanded a better understanding of the mechanisms whereby manganese induces neurodegenerative damage. Research from this laboratory has showed that chronic in vivo exposure to manganese, while reducing blood Fe concentrations, increases iron concentrations in the CSF, suggesting a likely compartment shift of iron from the blood circulation to brain extracellular fluids . Our recent in vitro studies have further demonstrated an increased iron transport at the blood-CSF barrier (Li et al., 2005) , a result that may be due to manganese interference on iron regulatory mechanism at the choroid plexus. From the chemistry point of view, manganese ions have many biochemical properties in common with iron including ionic radius, electrical charges in biological matrices, binding affinity for the carrier protein and subcellular accumulation in mitochondria Chen et al., 2001; Zheng et al., 1998) . Because of these similarities, manganese may compete with iron in IRP1 and thus alter the binding activity of IRP1 to the stem-loop containing TfR mRNAs (Chen et al., 2001; Zheng et al., 1998) . Since the mRNA encoding DMT1 contains a stem-loop structure, we hypothesized that manganese exposure may alter the binding of IRPs to DMT1 mRNA, thereby altering DMT1 expression in the choroid plexus; this could contribute to a distorted iron homeostasis in the CSF. The aims of this study were (1) to verify the existence of DMT1 in Z310 cells, a new cell line derived from rat choroidal epithelial cells (Zheng and Zhao, 2002) , (2) to investigate whether manganese exposure altered the DMT1 expression by using real-time RT-PCR to examine the expression of DMT1 mRNA and by Western blot analysis to determine DMT1 protein levels and (3) to study the effect of manganese exposure on protein-mRNA interactions between IRPs and DMT1 mRNA by electrophoretic mobility shift assay (EMSA).
Results

The presence of DMT1 in Z310 cell line by immunocytochemistry
Immunocytochemical studies demonstrated the presence of DMT1 in Z310 cells (Fig. 2B) . The punctate DMT1 staining was visibly present in cytoplasm. The control in the absence of primary antibody against DMT1 showed a negative staining ( Fig. 2A) .
2.2.
Manganese exposure increases mRNA and protein levels of DMT1 in vitro Real-time RT-PCR assay confirmed the presence of mRNA encoding DMT1 in the cultured Z310 cells. Quantitation by the real-time RT-PCR revealed that manganese treatment at 100 μM for 24 h and 48 h significantly increased the levels of DMT1 mRNA by 45.4% and 78.1%, respectively, as compared to the control (P < 0.05, Fig. 3 ). Treatment with 50 μM desferriox- amine (DFOM), an iron chelator, for 10 h, also resulted in a significant increase in DMT1 mRNA (Fig. 3) . The increase of DMT1 mRNA level in Z310 cells appeared to be concentrationrelated within the range of 100-200 μM (r = 0.870. P < 0.01, Fig.  4 ). To verify if the increased DMT1 mRNA level was indeed associated with an altered DMT1 protein in Z310 cells, the Western blot analysis was used to separate and quantify DMT1 proteins. Following manganese exposure at 100 μM for 48 h, a significant increase in cellular protein levels of DMT1 was observed (P < 0.05, Fig. 5 ). Noticeably, the antibody used in this experiment was against the C-terminal from 552 to 570 amino acid of DMT1, which is a distinguished part of DMT1 isoform I (Lee et al., 1998; Roth et al., 2000) . Thus, the single band with an estimated molecular weight of 65 kDa represents DMT1 proteins.
2.3.
Manganese exposure increases IRP binding to DMT1 mRNA in vitro
The increased protein level of DMT1 by manganese treatment could be due to manganese action at the transcriptional level to increase DMT1 gene expression or due to manganese modulation at the translational level to stabilize DMT1 protein expression. Since DMT1 mRNA has the stem-loop structure for IRP binding, it is possible that manganese treatment may enhance the binding of cytosolic IRPs to radiolabeled DMT1-IRE sequences. The EMSA results showed that manganese treatment did increase the binding of IRP1 to DMT1-IRE sequence as evidenced by (i) an increased density of proteinmRNA band on gels (Figs. 6A, B), (ii) a reduced density of this band in the presence of excess unlabeled DMT1-IRE sequences ( Fig. 6C ) and (iii) a shifted band when the cytosolic preparation was pretreated with antibody against IRP1 (Fig. 6D) . Thus, it appears likely that manganese stabilizes the binding of IRP1 to DMT1 mRNA, thereby increasing the expression of DMT1 proteins.
2.4.
Manganese exposure did not alter the status of DMT1 heterogeneous nuclear RNA (hnRNA)
The hnRNA represents newly transcribed, unspliced RNA and presents in a small percentage of total RNA in the nucleus of the cell (Danzi et al., 2003) . Only after properly spliced and processed does hnRNA become mRNA and enter the cytoplasm (Konarska and Sharp, 1986) . Therefore, the levels of hnRNA reflect the rate of gene transcription and RNA processing. To investigate whether manganese exposure affected DMT1 gene transcription, the levels of DMT1 hnRNA were determined by real-time RT-PCR. The amount of DMT1 hnRNA was normalized by the expression of β-actin hnRNA. Results showed that manganese treatment (50, 100 or 200 μM for 24 h) did not lead to any statistically significant changes in the expression of DMT1 hnRNA, as compared to the control group (Fig. 7) . Thus, it seemed unlikely that manganese altered DMT1 expression by acting on transcription of DMT1 DNA.
Discussion
The presence of DMT1 in the choroid plexus, the tissue where the blood-CSF barrier is located, has been demonstrated in the tissues from rats, mice and humans (Choudhuri et al., 2003; Gunshin et al., 1997; Kishi and Tabuchi, 1997; Knutson et al., 2004; Miller, 2004; Moos and Morgan, 2004; Siddappa et al., 2002) . Z310 cells were immortalized cells directly derived from rat choroidal epithelia (Zheng and Zhao, 2002) . Our current study by using immunocytochemical staining, Western blot and real-time RT-PCR techniques confirms the presence of DMT1 in this established choroidal epithelial cell line. Regulation of iron homeostasis in the body has long been regarded as a transferrin (Tf)-mediated process. However, studies in the last decade suggest that non-transferrinmediated mechanisms may also play a significant role in regulation of iron homeostasis. For example, animal models with DMT1 mutation, such as mk mice and Belgrade rats, have shown the defects in iron transport function, leading to anemia Fleming et al., 1997; Gruenheid et al., 1999; Su et al., 1998) . Studies on brain barriers have also suggested that iron can be transported across the BBB and BCB into the CNS through a non-Tf-mediated transport (Bradbury, 1997; Moos and Morgan, 2004; Takeda et al., 2002) . A recent study from this laboratory by using brain perfusion technique demonstrates that non-transferrinbound iron can get access to the CSF en route the choroid plexus by a yet unidentified mechanism (Deane et al., 2004) . Our observation of the presence of DMT1 in the choroidal Z310 cells is consistent with these earlier reports. Thus, it is highly likely that DMT1 may act as the transporter for free iron at the BCB. Manganese-induced neurotoxicities could be due to the distorted iron metabolism at both systemic and cellular levels (Chen et al., 2001; Zheng et al., 1998 Zheng et al., , 1999 Zheng and Zhao, 2001 ). An increased TfR expression and ensuing elevated iron transport at the BCB may partly explain the disrupted iron status in the CSF (Li et al., 2005 ). In the current study, we observed that, in addition to action on TfR, manganese exposure increased DMT1 levels in cultured choroidal epithelial cells. Real-time RT-PCR results revealed that the increase in DMT1 mRNA level was manganese dose-dependent and exposure time-associated. Western blot analyses further substantiated manganese-induced elevated protein level of DMT1 in the choroid plexus. While manganese exposure evidently causes the upregulation of TfR and DMT1 in the BCB, the questions as to which direction iron or manganese ions are transported by these two transporters and by what extent each transporter may contribute to a raised iron level in the CSF remain unanswered. Thus, much more work needs to be done to explore these mechanisms.
Increased DMT1 protein level following manganese exposure could be due to manganese action at the transcriptional level to increase DMT1 RNA production and/or RNA processing or at the post-transcriptional level by blocking DMT1 mRNA degradation. The mRNA encoding DMT1 contains a unique IRE stem-loop structure, which is subjected to the binding of cellular IRP1. Under iron sufficient condition, IRP1 possesses the [4Fe-4S] cluster in its active center and functions as aconitase to convert isocitrate in the tricarboxylic acid cycle. When the cells are in need of iron, the [4Fe-4S] configuration is turned into [3Fe-4S], which favors the protein to bind to IREcontaining mRNA including TfR mRNA (Rouault and Klausner, 1996; Zheng et al., 1998) . Earlier work from this laboratory has demonstrated that manganese, by replacing one iron in the [4Fe-4S] in IRP1, inhibits the enzyme's catalytic function and increases its binding activity to IRE-containing TfR mRNA; the event leads to an increased expression of TfR (Li et al., 2005; Zheng et al., 1998) . In this study, we used EMSA to determine the binding activity between cellular IRP1 and DMT1 mRNA whose sequence contains a stem-loop similar to TfR mRNA at 3′-UTR. When choroidal epithelial cells were exposed to manganese, a significant increase in binding of IRP1 to DMT1 stem-loop mRNAs was observed. Since the binding of IRP1 to IRE in DMT1 mRNA protects the mRNA sequence from degradation, it is reasonable to postulate that Fe-Mn interaction at the IRP1 may facilitate the binding of IRP1 to DMT1 mRNA, subsequently increase DMT1 mRNA stability and lead to the overproduction of DMT1 protein. The exact structural interaction between IRP proteins and IRE-containing DMT1 mRNAs awaits further exploration. However, our results are consistent with the studies conducted by Gunshin et al. (2001) , who have shown that DMT1 mRNA is regulated through stabilization by the IRE-IRP system, in an analogy to TfR regulation. Although the direction of iron transport that is regulated by DMT1 at the BCB remains unknown, the alteration of iron homeostasis in the CSF appeared to be the net result of IRP1-regulated events involving both TfR and DMT1. Noticeably, IRP2 also binds to the IRE motif to modulate iron homeostasis (Guo et al., 1995; Siddappa et al., 2003) . As reported recently, while both IRP1 and IRP2 are required for tissue iron regulation in vivo, in most cell lines, IRP1 seems to be a predominant factor in this protein-mRNA interaction in response to cellular iron status (Meyron-Holtz et al., 2004) . The elevated level of DMT1 mRNA by manganese treatment could also result from manganese action at DNA transcriptional level or due to upregulation of DMT1 mRNA. The hnRNA is the primary transcripts directly transcripted from genomic DNA. The hnRNA analysis is a useful technique to determine whether manganese acts on the gene transcription of DMT1. By assessing DMT1 hnRNA, we found no significant changes in DMT1 hnRNA levels following manganese exposure. Thus, it appears unlikely that the action of manganese on cellular DMT1 status is due to manganese action on DMT1 gene modulation.
In summary, the results of this study indicate that manganese exposure increases DMT1 expression in the blood-CSF barrier. Manganese treatment appears to increase the binding ability of cellular IRP1 to IRE-containing DMT1 mRNA, stabilize the DMT1 mRNA and promote the expression of DMT1 protein. The combined effect of DMT1 and TfR on iron transport at the BBB and BCB may contribute to manganeseelicited compartmental shift of iron from the blood to the CSF in manganese-induced neurodegenerative diseases.
4.
Experimental procedures
Cell culture and treatment
The Z310 choroidal epithelial cell line was established from murine choroid plexus and used in the experiments. The detailed procedure for cell culture and maintenance can be found in the previous publications (Li et al., 2005 ; Zheng and Zhao, 2002). In short, the cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in a humidified incubator with 95% air-5% CO 2 at 37°C. Mn (II) solution as MnCl 2 was prepared by directly dissolving MnCl 2 salts in distilled, deionized water at a concentration of 40 mM as the stoking solution. The working solutions were diluted from the stock on the day of use. The cells were exposed to 50, 100 or 200 μM Mn for 24 h for doseresponse study or 100 μM Mn for 12, 24 or 48 h for time course study. The dose regimen chosen as such was based on previous research in this particular area by this group or others (Li et al., 2005; Reaney and Smith, 2005; Zheng et al., 1999) . To create iron overloaded and iron deficiency conditions, cells were exposed to 20 μM hemin and 50 μM DFOM for 10 h, respectively.
Immunocytochemistry
The cells to be stained were cultured on a chamber for 2-3 days (Lab-Tek II chamber slide system, VWR). The cells were fixed in 4% paraformaldehyde in PBS solution followed by 3 washes with phosphate-buffered saline (PBS). The cell monolayer attached to a glass coverslip was pretreated with 0.3% hydrogen peroxide in methanol for 30 min at room temperature and incubated with 10% goat serum for 30 min. The cells were incubated with rabbit anti-rat DMT1 antibody (5 μg/ml) in PBS at room temperature for 30 min and rinsed with PBS for 3 times. The cultures were then incubated with biotinylated goat anti-rabbit secondary antibody (1:200) in PBS for 30 min. The negative control was stained with only secondary antibody. The specimens were further washed with PBS, stained with ABC reagent (VECTASTAIN, Vector Laboratories, UK) to form avidin-biotin-horseradish peroxidase complex. HRP was visualized using the substrate 3,3-diaminobenzidine (DAB, Vector Laboratories, UK) and examined under a microscope.
Western blot analysis of DMT1
Western blot experiments were carried out as previously described (Ke et al., 2003) . In short, cellular proteins were extracted in homogenization buffer containing 20 mM Tris, pH 7.5, 5 mM EGTA, 1% Triton X-100, 0.1% SDS, Protease Inhibitor Cocktail (Calbiochem, San Diego, CA). Samples were sonicated and assayed for protein concentrations by Bradford protein assay. A volume of protein extracts (40 μg of protein) was mixed with an equal volume of 2× sample buffer (0.125 M Tris, 4% SDS, 20% glycerol, 0.2% 2-mercaptoethanol, 0.01% bromophenol blue) and run on a 4-20% Tris-HCl linear gradient ready gel, electrophoresed and transferred to a PVDF membrane. The membrane was blocked with 5% dry milk in TBS (Trisbuffered saline) and incubated with an antibody directly against DMT1 with IRE (ADI, San Antonio, CA). The membrane was stained with a horseradish-peroxidase-conjugated goat anti-rabbit IgG antibody (1:2000) and developed using enhanced chemiluminescence (ECL, Amersham Biosciences, NJ). β-actin (42 kDa) was used as an internal control. Band intensity was quantified using UN-SCAN-IT TM (Version 5.1) software (Silk Scientific Inc., Orem, Utah).
Electrophoretic mobility shift assay (EMSA)
EMSA was conducted to determine the interaction between IRPs and mRNAs containing IRE according to manufacturer's direction (Fermentas Life Science, Hanover, MD). The procedure consisted of four major steps.
(1) Extraction of S100 cytoplasmic protein. Z310 cells with or without manganese exposure were harvested and homogenized followed by centrifugation at 100,000 × g for 1 h. The supernatant was dialyzed for 8 h against 20 volumes of degassed dialysis buffer composed of 20 mM HEPES, 0.1 M KCl, 20% (v/v) glycerol, 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM dithiothreitol (DTT) using Spectra/Pro 16-well MicroDialyzer (150 μl capacity, Spectrum Laboratories, Rancho Dominguez, CA). The S100 cytoplasmic extracts were stored at −80°C until use (Lin et al., 2001) .
(2) Preparation of RNAs containing stem-loop structure. The DNA oligonucleotide template T7-1 (sequence: 5′-TAATA CGACTC ACTATA-3′) was annealed to DMT1-IRE (2 μM) (sequence: 5′-AAC CAT AGA AAC ACA CTG GCT CTG ATG GCT TCT CCC TAT AGT GAG TCG TAT TA-3′) (customer synthesized by IDT, Coralville, IA) in 50 μl anneal buffer (10 mM Tris-HCl pH 7.5, 10 mM MgCl 2 ) (Gunshin et al., 2001) . The mixture was heated to and maintained at 95°C for 5 min and then cooled to less than 35°C before operating the next step. The transcription reaction was carried out in a total of 20 μl with 2 μl annealed template, 1 μl T7 RNA polymerase (20 units), 1 μl of ribonuclease inhibitor, 1 μl of 10 mM ATP, GTP and CTP mix, 2.4 μl 100 μM UTP and 5 μl of [α-32 P] UTP (50 μCi at 10 mCi/ml) for 1 h at 37°C followed by RNA precipitation in chloroform. The labeled RNAs containing DMT1 stem-loop structure were frozen at −80°C until use.
(3) EMSA. The S100 cytoplasmic extracts were incubated with [ 32 P]-labeled DMT1-IRE-containing RNA in a band shift buffer (25 mM K-HEPES pH 7.6 at 25°C, 150 mM CH 3 COOK, 1.5 mM Mg Cl 2 , 5% glycerol) at 22°C for 30 min. RNA-protein complexes were separated by electrophoresis on a nondenaturing 6% polyacrylamide gel at 100 V for 3 h. After drying, the gels were exposed to Kodak BioMax XAR film. The density of protein-RNA bound bands was quantified using UN-SCAN-ITTM gel Version 5.1 software. -P] labeled DMT1-IRE was mixed with either 1×, 2× or 3× excess of unlabeled competitor RNA. The mixture was incubated with S100 cytoplasmic extracts at 22°C for 30 min and run on gel. Supershift was performed by adding IRP1 antibody (a kind gift from Dr. Tracey A. Rouault, NICHD) and IRP2 antibody (a kind gift from Dr. Elizabeth A. Leibold, University of Utah.) into the reaction system. The bands were obtained in the same method as described before.
4.5.
Determination of heterogeneous nuclear RNA (hnRNA)
The first product of transcription is the primary transcript or hnRNA, which includes both introns and exons. Total RNA from Z310 cells was used in reverse transcription reaction with a reverse primer (5′-ATTGCCACCGCTGGTATCTT-3′; GenBank accession no. AF008439) that corresponds to intronic sequence. DNase I was used to digest DNA. RT-PCR was performed with both forward primer (5′-ATTGCCATCATCCC-TACCCT-3′; GenBank accession no. AF008439) that corresponds to exonic sequence and reverse primer as above. These primers amplified only DMT1 hnRNA. After an initial activation step at 95°C for 15 min, amplification was done with 40 cycles; melting step at 95°C for 30 s; annealing at 60°C for 1 min; and extension at 72°C for 30 s. An aliquot (20 μl) of the PCR reaction product was run on a 2% agarose gel with ethidium bromide. β-actin hnRNA was used as an internal control (Danzi et al., 2003) . All RT-PCR reactions were done in triplicates.
4.6.
Quantitative real-time RT-PCR analysis DMT1 mRNA Levels of DMT1 mRNA were quantified using real-time RT-PCR analysis as described by Walker (2001) . Briefly, total RNA was isolated from Z310 cells using Tri-Reagent following the manufacturer's direction (Molecular Research Center, Cincinnati, OH). An aliquot (2 μg) of RNA was reverse-transcribed with MuLV reverse transcriptase (Applied Biosystems, Foster City, CA) and oligo-dT primers. The forward and reverse primers for selected genes were designed using Primer Express 2.0 software (Applied Biosystems, Foster City, CA). The ABsolute QPCR SYBR green Mix kit (ABgene, Rochester, New York) was used for real-time RT-PCR analysis. The amplification was carried out in the Mx3000P Real-Time PCR System (Stratagene, La Jolla, CA). Amplification conditions were 15 min at 95°C followed by 40 cycles of 30 s at 95°C, 1 min at 60°C and 30 s at 72°C. Primers sequences used for real-time RT-PCR analysis were: for rat DMT1 using a forward primer 5′-CAG TGC TCT GTA CGT AAC CTG TAA GC-3′ and reverse primer 5′-CGC AGA AGA ACG AGG ACC AA-3′ (GenBank accession no. AF008439), which specifically amplified DMT1 containing IRE; for rat GAPDH, used as an internal control, using a forward primer 5′-CCT GGA GAA ACC TGC CAA GTA T-3′ and reverse primer 5′-AGC CCA GGA TGC CCT TTA GT-3′ (GenBank accession no. NM_017008).
The relative differences in gene expression between groups were expressed using cycle time (Ct) values; these Ct values of the interested genes were first normalized with that of GAPDH in the same sample, and then the relative differences between control and treatment groups were calculated and expressed as relative increases setting the control as 100%. Assuming that the Ct value is reflective of the initial starting copy and that there is 100% efficiency, a difference of one cycle is equivalent to a two-fold difference in starting copy (Liu et al., 2004a,b; Livak and Schmittgen, 2001; Walker, 2001 ).
Statistical analysis
All data are expressed as mean ± SE. The replicates of experiments conducted in the same day were referred as n = 1; three or four such replicates on different dates were used for statistical analyses. Statistical analyses of the differences between groups were carried out by one-way ANOVA using SPSS 12.0 statistic package for Windows. The differences between two means were considered significant if P values were equal or less than 0.05.
Materials
Chemicals were obtained from the following sources: DMEM, fetal bovine serum (FBS), penicillin and streptomycin, gentamycin, RNase-free DNase I and 0.25% Trypsin-1 mM EDTA (TE) from Invitrogen Life Technologies (Carlsbad, CA); rabbit antirat DMT1 antibody from Alpha Diagnostic International (San Antonio, CA); ATP, GTP, CTP and UTP (NTPs), [α-32 P]UTP, T7 polymerase and peroxidase-labeled anti-rat secondary antibody from Amersham (Piscataway, NJ); SDS from Bio-Rad (Hercules, CA); bromophenol blue from Fisher Scientific Company (Fair Lawn, NJ); dithiothreitol (DTT), DFOM, hemin, EDTA, HEPES, 2-mercaptoethanol, paraformaldehyde, phenylmethylsulfonyl fluoride (PMSF), polyacrylamide, tetramethylethylenediamine (TEMED), Triton X-100 and all other chemicals from Sigma Chemicals (St. Louis, MO). All reagents were of analytical grade, HPLC grade or the best available pharmaceutical grade.
